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ABSTRACT
High-risk human papillomaviruses (HPV) can be present and cooperate with Epstein–Barr virus (EBV) to promote 
the onset and/or progression of various cancers including cervical, breast, head and neck as well as colorectal. In 
this investigation, we explored the co-prevalence of high-risk HPV and EBV in 74 breast cancer tissues from 
Qatari women using polymerase chain reaction. We found that high-risk HPV and EBV are present in 48/74 
(65%) and 36/74 (49%) of the cases, respectively. While we noted that the presence of HPV presence is 
associated with triple-negative breast cancer (TNBC) (p = .008), however, the presence of EBV did not correlate 
with any breast cancer subgroup. Moreover, our data revealed that high-risk HPV and EBV are co-present in 35/ 
74 (47%) of the samples and their co-presence is significantly associated with tumor grade (p = .04) and tumor 
stage (p = .04). These data indicate that HPV and EBV are commonly co-present in breast cancer and their 
association could be linked with a more aggressive tumor phenotype. Thus, further investigations are essential 
to understand the underlying mechanisms of HPV and EBV cooperation in breast carcinogenesis.
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Introduction
Breast cancer, is the most commonly diagnosed type of malig-
nancy among women worldwide including the Middle East (ME) 
region and Qatar, accounting for around 1/4th of all cancer cases.1 
In comparison to breast cancer cases in the West, the ME region 
has the highest incidence where women are affected at a relatively 
younger age (<50 years) and usually present to the clinic with 
advanced stage disease and aggressive phenotype.2–4 Along with 
genetic and environmental factors, it is estimated that around 20% 
of human cancers are associated with infectious agents including 
oncoviruses especially high-risk human papillomaviruses (HPVs) 
and Epstein-Barr virus (EBV) which could initiate the onset and 
progression of different types of human carcinomas.5–8
Today, it well-known that high-risk HPVs are linked with the 
development and progression of several cancers including cervical, 
colorectal, head and neck (HN) in addition to breast cancers.9–12 
More interestingly, it was pointed out that the presence of high- 
risk HPVs is linked with vascular invasion, lymph node metastases 
and tumor phenotype in different types of human carcinomas 
including cervical, HN and breast.11,13-16 In this context, it has 
been reported that E6/E7 oncoproteins of high-risk HPV type 16, 
which is the most frequent HPV type, can converts noninvasive 
and non-metastatic breast cancer cells into invasive and metastatic 
form.17 On the other hand, EBV infection is also associated with 
several types of epithelial carcinomas including nasopharyngeal 
(NPC), breast, cervical and gastric cancer.18 EBNA1 and LMP1 are 
oncogenic proteins of EBV that provoke cellular proliferation and 
motility, inhibit apoptosis, promote cellular motility and angio-
genesis, thus, indicating the role of EBV in carcinogenesis.19–21
A study showed that E6/E7 oncoproteins of HPV interact with 
Nucleophosmin, a nucleolar protein, to enhance proliferation and 
inhibition of differentiation of E6/E7 expressing cells.22 Likewise, 
infection with a single type of high-risk HPV alone is not enough 
to incite neoplastic transformation; high-risk HPV-infected cells 
either have to endure genetic transformation and/or co-infection 
with another oncoviruses for complete cellular transformation 
resulting in the onset and development of tumor.23–29 Earlier 
studies demonstrated that high-risk HPVs and EBV are co- pre-
sent in human breast cancer worldwide including the ME; and 
their incidence is generally associated with an aggressive 
phenotype.30,31 While, a few studies failed to detect high-risk 
HPVs in human breast cancer as well as normal mammary 
tissues.32,33 Based on previous studies and our work on the role 
of HPV and EBV in the initiation of various cancers including HN, 
colorectal, cervical and breast,26,29,34-36 we explored the co- 
presence of high-risk HPVs and EBV in breast cancer in Qatari 
women. Our data revealed that 47% of the examined samples are 
positive for both HPV and EBV and their co-presence is signifi-
cantly associated with tumor grade and stage in comparison with 
HPV and EBV alone.
Materials and methods
Sample collection and DNA extraction
Breast cancer samples from a total of 505 Qatari female patients 
were collected over a 12-year period (January 2008-December 
2019), out of which 9 patients had received neoadjuvant che-
motherapy prior to their breast surgery. Seventy-four patients 
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received surgical treatment at Hamad General Hospital, Qatar, 
which were included in the study. All the tumors were graded 
according to the Nottingham histological grade (modified Scarff- 
Bloom-Richardson grade).37 The tumors were considered posi-
tive for estrogen (ER) and progesterone receptors (PR) if nuclear 
positivity was observed in >1% of tumor cells.38 HER2 positivity 
(score 3+) was defined as intense, complete, circumferential 
membranous expression in >10% tumor cells.39 Equivocal 
(score 2+) was defined as a weak, complete membranous stain-
ing in >10% of tumor cells. The tumor cells with scores 0–1 
+ were considered negative for HER2. The proliferation index 
was assessed using Ki-67 proliferation marker (MIB1 antibody). 
The tumors were considered highly proliferative if Ki-67 > 20% 
of tumor cells. Tumor samples were classified into four molecu-
lar subtypes (Luminal A, luminal B, HER2-positive and triple- 
negative) based on the status of ER, PR, HER2 and Ki-67.
All samples (punch samples of 2 mm thickness) were taken 
from formalin-fixed paraffin-embedded (FFPE) tissues from sur-
gically removed and pathologically confirmed breast carcinomas. 
The samples were retrieved from Qatar University (QU) and the 
pathology archive of the Department of Laboratory Medicine and 
Pathology, Hamad General Hospital (HMC), Qatar, after the 
approval of the Ethical Committees of QU & HMC (QUCG- 
CMED-2018\2019-3; HMC:24-2-2019, Doha, Qatar).
Exclusion criteria included other nationalities, Qatari males, 
slides and blocks of patients that received surgical intervention 
outside Hamad General Hospital and presented to the histopathol-
ogy lab for second opinion, breast core/true-cut/stereotactic 
biopsy, and lymph node biopsy/skin biopsy diagnosed with meta-
static breast carcinoma, repeated excisions from the same patient, 
specimens of patients post chemotherapy with complete resolu-
tion of the cancer and microscopic tumors less than 1 cm in 
addition to the tumors that are presented within one paraffin 
block.
The Thermo Scientific GeneJET FFPE DNA Purification Kit 
was used to extract DNA from FFPE tissues according to the 
manufacturer’s instructions (ThermoFisher Scientific, USA). 
Briefly, FFPE sections underwent enzymatic digestion 
(200 µL of Digestion Buffer) and lysis using 20 µL Proteinase 
K solution to release genomic DNA. The released DNA was de- 
crosslinked by heat incubation at 90°C for 40 minutes. The 
resulting solution was then centrifuged and the supernatant 
containing DNA was mixed with 200 µL Binding Buffer. After 
addition of ethanol (96%), the lysate was added into the pur-
ification column. The adsorbed DNA was washed to remove 
contaminants and then eluted with 60 µL Elution Buffer.
HPV and EBV detection by PCR
Genotyping and detection of the presence of HPV and EBV was 
done using specific primers for high-risk HPV types (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56 and 58) of E6/E7 region and for EBV 
genes, EBNA1 and LMP1 as previously described.40,41 GAPDH 
was used as an internal control (Figures 1 and 2). Analysis was 
performed as previously described by our group.40,41
PCR was performed using the Invitrogen Platinum II 
Hot-Start Green PCR Master Mix (2X) (ThermoFisher 
Scientific, USA). HPV and EBV genes were amplified for 
an initial denaturation at 94°C for 2 mins followed by 40 
cycles of 94°C for 30s, annealing at temperatures ranging 
from 50 to 62°C for 30s depending on each primer’s melt-
ing temperature as previously described,40,41 and 72°C for 
30s with a final incubation for 10 mins at 72°C. The PCR 
product from each exon was resolved using 1.5% agarose 
gel electrophoresis and visualized using iBrightCL1000 
Imaging System (ThermoFisher). In each experiment, nega-
tive control (instead of DNA, MDA-MB-453 cell line42 and 
sterile water) and positive control (Hela cell line for L1 
region43 and normal oral epithelial (NOE) cell line trans-
fected with E6/E7 of HPV type 16 for E6/E7 region23) were 
used.
Statistical analysis
Statistical analysis was performed using IBM Statistical 
Package for the Social Sciences (version 25). Data were 
calculated as non-parametric files. To assess the significance 
of HPV and EBV association we utilized χ2 test with Yates 
correction. Further, we utilized χ2 test with Yates correction 
to assess the significance of the association between clinic- 
pathological data (patient’s age, Nottingham histological 
grade and tumor stage) in correlation with the presence/co- 
presence of HPVs and EBV. Statistical significance was 
achieved at p < .05.
Results
Clinicopathological characteristics of the cohort
The clinicopathological characteristics of the cohort are sum-
marized in Table 1. The mean age of all patients is 55.3 
(standard deviation (SD), ±12.4) years. Most of the patients 
Figure 1. Representative PCR reactions for high-risk HPV-subtypes in 15 different 
breast cancer samples.
Figure 2. Representative PCR reactions for EBV (EBNA1 and LMP1) in 15 different 
breast cancer samples.
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(66%) are aged >50 years. Axillary lymph nodes were involved 
in 41% of patients (Table 1).
The majority of patients had invasive ductal carcinomas 
(IDC), no special type (NST) (60 cases, 81%) while 8 patients 
(11%) were diagnosed with invasive lobular carcinoma (ILC) 
and five patients (7%) with mucinous carcinomas. The hor-
mone receptor status was available for 72 patients; 59 (80%) 
and 54 (73%) of the patients expressed estrogen and progester-
one receptors, respectively. With reference to HER2 status, it 
was available for 72 patients of which 8 (11%) had overexpres-
sion (score 3+), 8 (11%) had equivocal expression (score 2+) 
and 56 (76%) lacked HER2 expression (scores 0–1+). The 
status for Ki-67 proliferative index was available for 52 
patients, 19 of which had low proliferation rate (<10%), 10 
had intermediate (10–20%) and the remaining 23 had a high 
(>20%) proliferation rate. All cases were categorized into four 
molecular subtypes: Luminal A (32 cases, 43%), Luminal B (28 
cases, 38%), HER2+ (2 cases, 3%) and triple-negative (10 cases, 
14%) (Table 1).
The status of high-risk HPV and EBV and their association 
with clinicopathological characteristics
Forty-eight of the 74 samples in our cohort are positive for 
high-risk HPVs (64.8%) (Table 2); the most commonly present 
high-risk HPVs are HPV52 (51%) followed by HPV56 (44%), 
HPV45 (22%), HPV58 (15%), HPV18 (11%), HPV35 (3%) and 
HPV39 (1%) (Figure 3). HPV types 16, 31, 33 and 51 were not 
detected in our examined samples (Figure 3). On the other 
hand, we found that 36/74 of the samples are positive for EBV 
(49%) (Table 2); of these 36 cases, 33/74 (45%) and 28/74 (38%) 
are positive for EBNA1 and LMP1 of EBV, respectively. 
Meanwhile, we noted a significant correlation between EBV 
and various HPV types: HPV18 (p = .03), HPV35 (p = .03), 
HPV52 (p = .03) and HPV56 (p = .003) (Table 3). Furthermore, 
our data revealed that 14/74 (19%) cases are positive for two 
HPV subtypes; the most commonly present combination is 
HPV52/56 (24/74, 32%), followed by HPV52/45 (13/74, 18%), 
HPV52/58 (8.74, 11%), HPV52/18 (7/74, 9%) and HPV52/35 
(1/74, 1%) (Figure 4). Finally, we observed that, 18/74 (24%) of 
the samples are positive for more than two HPV subtypes; and 
the most frequent combinations are: HPV52/56/45 (11/74, 
15%), HPV52/56/58 (7/74, 9%), HPV52/56/18 (6/74, 8%) and 
HPV52/56/59 (1/74, 1%) (Figure 4).
More significantly, our data revealed that the co-presence of 
EBV and high-risk HPV is detected in 47% (35/74) of breast 
cancer cases (Table 2); and there is a significant correlation 
between the coincidence of EBV with various HPV types 
(HPVs- 18, 45, 52, 56 and 58) in the 74 breast cancer samples 
(p < .001).
Table 1. Clinicopathological characteristics of patients with breast cancer.
Characteristic Categories
Number 
(%)
Age ≤50 25 (34)
>50 49 (66)
Histopathological Subtypes of Breast 
Cancer
Invasive Ductal 
Carcinoma
60 (81)
Invasive Lobular 
Carcinoma
8 (11)
Mucinous Carcinoma 5 (7)
Unknown 1 (1)
Nottingham Histological Grade I 14 (19)
II 40 (54)
III 18 (24)
Unknown 2 (3)
Tumor (pT) Stage pT1 18 (24)
pT2 21 (28)
pT3 6 (8)
pT4 2 (3)
Unknown 27 (37)
Lymph Node Involvement Positive 30 (40)
Negative 37 (50)
Unknown 7 (10)
Estrogen Receptor (ER) Status ER+ 59 (80)
ER- 13 (17)
Unknown 2 (3)
Progesterone Receptor (PR) Status PR+ 54 (73)
PR- 18 (24)
Unknown 2 (3)
HER2 Status Positive (3+) 8 (11)
Equivocal (2+) 8 (11)
Negative (0–1+) 56 (76)
Unknown 2 (3)
Ki-67 Proliferative Index (PI) Low (<10%) PI 19 (26)
Intermediate (10–20%) 
PI
10 (13)
High (>20%) PI 23 (31)
Unknown 22 (30)
Molecular Classification of Breast 
Cancer
Luminal A 32 (43)
Luminal B 28 (38)
HER2+ 2 (3)
Triple Negative 10 (13)
Unknown 2 (3)
HPV Expression Invasive Ductal 
Carcinoma
38 (51)
Invasive Lobular 
Carcinoma
5 (7)
Mucinous Carcinoma 4 (5)
EBV Expression Invasive Ductal 
Carcinoma
21 (28)
Invasive Lobular 
Carcinoma
1 (1)
Mucinous Carcinoma 3 (4)
Table 2. Prevalence of high-risk HPVs and EBV in Qatari breast cancer patients.
Single Infection               Multiple Infection
HPV EBV HPV + and EBV+
65% 49% 47%
Figure 3. Distribution of each high-risk HPV subtype in Qatari breast cancer 
samples. PCR analysis included 74 breast cancer samples revealing that the 
most frequent HPV subtypes are 52, 56 and 45.
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Regarding the clinicopathological characteristics and their 
association with high-risk HPV/EBV co-presence, we noted 
that high-risk HPVs positivity (HPV+/EBV-) significantly cor-
relates with triple-negative breast cancer subtype (p = .008) 
(Table 4); while, EBV positivity alone (HPV-/EBV+) as well as 
lack of both HPV and EBV (HPV-/EBV-) did not correlate 
with any clinicopathological feature. More importantly, our 
data revealed that the co-presence of high-risk HPVs and 
EBV (HPV+/EBV+) is associated with luminal A (p = .02) 
subtype in addition to tumor grade (p = .04) and tumor stage 
(p = .04) (Table 5); nevertheless, there is no association with 
lymph node involvement (p = .85).
Discussion
To the best of our knowledge, this is the first study on the 
presence/co-presence of high-risk HPVs and EBV in human 
breast cancer and its association with tumor grade and stage in 
the Gulf region. It is well known that oncogenic proteins of 
high-risk HPV can stimulate inflammation, making it 
a plausible candidate for the onset and progression of different 
types of human carcinomas including breast.44 In this study, 
we analyzed 74 breast cancer samples for the presence of high- 
risk HPVs, we found that 65% of our samples are positive for 
these oncoviruses. Several studies reported the presence of 
high-risk HPVs in human breast cancer patients worldwide 
including the ME region, with prevalence ranging from 4 to 
86%.11,42,45-48 More specifically, our data is supported by sev-
eral investigations in the ME region including one from Syria 
and another one from Turkey, where a high frequency of high- 
risk HPVs of 61% and 74%, respectively, were reported.11,49 
Moreover, one investigation from Iraq, showed that HPVs are 
present in 46% of breast cancer samples from Iraqi women.50 
Additionally, a few studies from Iran showed varying HPV 
prevalence in breast cancer (14–49%) in Iranian women.45,51- 
53 On the other hand, it is important to highlight that a study 
on cervical samples in Qatari women found HPV prevalence of 
55%, which also supports our data.54
Indeed, one of the key findings in our study is the predomi-
nance of HPV genotypes – 52 and −56 in breast cancer from 
Qatari women. Accordingly, a study using cervical samples 
revealed that high-risk HPV type 56 is one of the most frequent 
type in Qatari women.55 More interestingly, two studies one in 
Bahraini women and another one in Omani women with cervi-
cal cancer, reported that HPV52 is the most prevalent subtype in 
Bahrain and Oman.56 However, studies on cervical cancer sam-
ples from other Gulf countries showed that high-risk HPV types 
68 and 73 are the most prevalent in the Kingdom of Saudi 
Arabia,57 while in Kuwait HPVs 16, 66 and 33 are common.58 
Although, it is important to emphasize that HPV types 16 and 18 
are the most frequently expressed genotypes in cancers 
worldwide;46,47 in our study we did not detect HPV type 16, 
while HPV type 18 had a low prevalence of 11%. Other studies 
also had similar data where, HPV type18 is present in around 
Table 3. Presence of EBV and HPV-subtypes in Qatari breast cancer patients.
Samples No. of Cases
High-Risk HPV Types
16 18 31 33 35 39 45 51 52 56 58
EBV (+) 36 0 7 0 0 1 0 15 0 27 24 10
EBV (-) 38 0 1 0 0 1 0 1 0 11 9 1
Total 74 0 8 0 0 2 0 16 0 38 33 11
p-value N/A 0.02* N/A N/A 0.98 N/A 0.0001* N/A 0.0001* 0.0005* 0.007*
Comparison was made between presence/absence of EBV (EBV+/EBV-) with high-risk HPV subtypes. 
*indicates significant p-values (<0.05). 
N/A denotes Not Applicable as χ2 test is invalid in these cases, since value is 0.
Figure 4. Distribution of HPVs co-infection in Qatari breast cancer cohort (n = 74). 
The graph illustrates that the two most common high-risk HPVs are HPV52/56 (24/ 
74 cases) while co-infection with more than two HPVs is HPV52/56/45 (11/74 cases).
Table 4. Correlation between clinicopathological characteristics and HPV 
positivity.
Molecular Subtypes of Breast Cancer                             
Subtypes HPV Positive (%) HPV Negative (%) p-value
Luminal A 23 (32) 9 (12) p = .103
Luminal B 18 (25) 10 (14) p = .476
HER2-Positive 2 (3) 0 (0) p = .140
Triple Negative 3 (4) 7 (10) p = .008*
Total 46 (64) 26 (36)
Nottingham Histological Grade
Grade
I 11 (15) 3 (4) p = .354
II 23 (32) 17 (24)
III 12 (17) 6 (8)
Total 46 (64) 26 (36)
Tumor Stage
Stage
Early Stage (I–II) 26 (55) 13 (28) p = .251
Advanced Stage (III–IV) 3 (7) 5 (10)
Total 29 (62) 18 (38)
Comparison was made between presence/absence of HPV (HPV+/HPV-) and 
clinicopathological characteristics. 
*indicates significant p-values (p < 0.05).
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12% of breast cancer cases.16,46 A study in the Chinese popula-
tion did not detect the presence of HPV16 and 18 in breast 
cancer samples.59 Moreover, a study in Australia performed 
PCR on breast cancer samples and identified HPV18 as the 
most prevalent subtype in breast cancer specimens.60 
Therefore, the difference in HPV prevalence and genotype dis-
tribution can be attributed to geographical location, sample size 
as well as methodological differences.47,61 Regarding breast can-
cer subtypes and their association with high-risk HPVs, our data 
show high prevalence of HPV DNA in Luminal A and B cancer 
tissues showing high levels of Ki67 expression, which is sup-
ported by De Carolis et al., (2019).62 Furthermore, according to 
previous reports and concordant with our data, HPV presence is 
significantly associated with TNBC.48,62-64 In this context, it is 
important to emphasize that TNBC form a highly invasive breast 
cancer subgroup; thus, we have demonstrated that E6/E7 onco-
proteins of high-risk HPVs converts noninvasive and non- 
metastatic breast cancer cells into invasive and metastatic 
ones.17 Thus, our new finding concurs with our previous work 
regarding the role of E6/E7 in breast cancer cells.
Vis-a vis the presence of EBV in human breast cancer, it has 
been revealed that EBV is present in (30–50%) of this cancer 
cases worldwide.65–69 Studies in Turkey and Syria reported 
58%70 and 52%71 EBV positivity in breast cancer, respectively. 
While in Egypt, 45% of breast cancer cases were positive for 
EBV.72 Additionally, Tunisia and Iraq reported EBV presence in 
breast cancer in 27%73 and 28%72 of the examined cases, respec-
tively. Recently, studies in breast cancer from Iran reported 27% 
of EBV DNA in their samples.74,75 In our study, we report that 
EBV is present in approximately 49% of breast cancer cases in 
Qatari women. Therefore, our data indicate the prevalence of 
EBV in breast cancer tissues in Qatar is similar to the incidence 
present worldwide including the ME region.
Intriguingly, based on previous works, including ours, co- 
presence of high-risk HPV and EBV can play an important role 
in the onset and progression of different cancers including oral, 
colorectal, cervical as well as breast.11,26,27,29,35,76 In concordance, 
in our present investigation, we report that 47% of breast cancer 
cases, from Qatari women, are co-infected with both HPVs and 
EBV. Our previous work in Syrian samples pointed out that 
high-risk HPVs and EBV are co-present in 32% of breast cancer 
samples from Syrian women.26 While an earlier study from 
Pakistan revealed that HPVs and EBV are co-present in approxi-
mately 9% of breast cancer samples from Pakistani women.77 On 
the other hand, it is important to highlight that the presence of 
EBV alone is not shown to be associated with tumor stage, 
histological grade, molecular subtypes or nodal status; as pre-
viously reported by other investigations.78 However, HPVs and 
EBV have been considered as risk factors for TNBC;79 we found 
a significant association between HPVs and EBV co-presence 
and TNBC as well as luminal A subtypes. Moreover, studies 
showed co-presence of HPVs and EBV to be correlated with 
advanced breast Nottingham histological grade65 and aggressive 
phenotype.80 Likewise, we herein demonstrate for the first time 
that the co-presence of high-risk HPVs and EBV is associated 
with advanced tumor stage and grade (p = .04); indicating the 
possible cooperative role of high-risk HPVs and EBV oncopro-
teins in the initiation and/or progression of certain subtypes of 
human breast cancer as previously reported by several 
studies.65,77,81,82 We have pointed out earlier that oncoproteins 
of HPVs (E5 and E6/E7) and EBV (LMP1 and/or EBNA1) can 
interact and cooperate in the initiation and/or progression of 
human oral carcinomas via the EMT event;25 thus indicating 
a similar mechanism in the pathogenesis of human breast malig-
nancy. Based on HPVs and EBV role in the pathogenesis of 
cancer as discussed above, we postulate that oncoproteins of 
HPVs can interact with those of EBV (LMP1 and/or EBNA1) 
and result in progression and metastasis by enhancing the EMT 
event of different types of cancers including breast, as recently 
demonstrated in other types of cancers, such as colorectal and 
HN.18,35,83
The current study has several limitations. Firstly, we did not 
have a proper control group for the study (e.g. reduction mam-
moplasty samples); however, using the same methodology, we 
recently reported the prevalence of EBV and HPV in a large 
cohort of healthy blood donors from Qatar.40 Although Qatari 
females were under-represented, we found a similar prevalence 
of both viruses. Secondly, access to breast cancer tissue samples 
was restricted, which led us to apply only one method (PCR- 
based) for EBV and HPV assessment. Of note, our previous 
studies exploring HPV and EBV in different types of cancers 
using PCR and IHC yielded comparable results.29,41,84,85
Conclusions
In conclusion, although the sample size used in the study is 
relatively small, this report indicates the co-presence of HPVs 
Table 5. The correlation between clinicopathological characteristics and EBV/HPV 
status (the HPV/EBV positive group was compared with other subgroups of breast 
cancer with various HPV/EBV status).
Molecular Subtypes of Breast Cancer                             
Subtypes HPV±/EBV± (%) HPV+/EBV+ (%) p-value
Luminal A 19 (26.3) 13 (18) p = .02*
Luminal B 10 (13.9) 18 (0.3) p = .08
HER2-Positive 2 (2.8) 0 (0) p = .06
Triple Negative 2 (2.8) 8 (11.1) p = .04*
Total 33 (45.8) 39 (54.2)
Nottingham Histological Grade
Grade
I 4 (5.5) 10 (13.9) p = .04*
II 27 (37.5) 13 (18.1)
III 10 (13.9) 8 (11.1)
Total 41 (56.9) 31 (43.1)
Tumor Stage
Stages
Early Stage (I–II) 20 (42.5) 19 (40.4) p = .04*
Advanced Stage (III–IV) 1 (2.1) 7 (14.9)
Total 21 (44.6) 26 (55.3)
Lymph Node Involvement
Status
Positive 16 (23.9) 14 (20.9) p = .85
Negative 20 (29.8) 17 (25.3)
Total 36 (53.7) 31 (46.2)
Tumor Type
IDC 27 (37) 32 (43.8) p = .53
ILC 2 (2.7) 4 (5.5)
Others 5 (6.9) 3 (4.1)
Total 34 (46.6) 39 (53.4)
*indicates significant p-values (<0.05). 
HPV+/EBV+ denotes a co-presence of HPV and EBV. HPV±/EBV± indicates 
a combination of HPV+/EBV- (HPV presence/EBV absence), HPV-/EBV+ (HPV 
absence/EBV presence) and HPV-/EBV- (lack of both HPV and EBV).
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and EBV in breast cancer in this region and implies that it is 
associated with tumor grade and stage. Our investigation sug-
gests that HPVs and future EBV vaccines can be used to 
prevent the development and progression of certain subtypes 
of breast cancer in the population of the Gulf region including 
Qatar. However, it is important to take into consideration the 
most frequent HPV types in this region in order to select the 
suitable HPV vaccine. Meanwhile, we believe that future inves-
tigations with a larger cohort from different countries of the 
ME region including Qatar are needed to confirm the co- 
presence and HPV subtypes of these oncoviruses in breast 
cancer and therefore to elucidate the exact role of EBV and 
high-risk HPVs cooperation in breast carcinogenesis.
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